구독하기
연구 모델
모델 라이브러리
연구용 마우스 모델
맞춤형 모델 제작
전임상 연구지원
완전 인간 항체 라이브러리
huSPAST-HA-R499H Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huSPAST-HA-R499H Mouse
제품명
huSPAST-HA-R499H Mouse
제품 ID
C002144
품종 계통
C57BL/6Cya-Spasttm2(HA tag-hSPAST*R499H)/Cya
Backgroud
C57BL/6Cya
상태
이 마우스 계통을 논문에서 사용할 경우, “huSPAST-HA-R499H Mouse (카탈로그 번호 C002144)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
기본 정보
관련 자료
기본 정보
유전자명
유전자 별칭
FSP2, SPG4, ADPSP
NCBI ID
염색체
Chr 2
MGI ID
더보기
Datasheet
품종 계통 설명
Hereditary spastic paraplegia (HSP) is a hereditary neurodegenerative disease characterized pathologically by retrograde axonal degeneration of the corticospinal tract and the posterior columns of the spinal cord. Its clinical manifestations include progressive spastic weakness of both lower limbs, scissor gait, hyperreflexia, and positive pathological signs. The prevalence of autosomal dominant HSP is approximately 1–5 per 100,000, and it usually begins in young adulthood. SPG4, caused by mutations in the SPAST gene, is the most common autosomal dominant HSP subtype, accounting for about 40% of all autosomal dominant HSP families [1-3], and it is also the most common subtype in Chinese autosomal dominant HSP cohorts [4]. Spastin, encoded by SPAST, is a member of the AAA+ ATPase family. By severing microtubules, it regulates microtubule length, dynamics, and axonal transport, and is essential for maintaining cytoskeletal homeostasis in long axons [5]. SPAST mutations are predominantly missense, nonsense, and splice-site variants; whole-gene deletions can also cause the disease. Loss of function (haploinsufficiency) is the primary pathogenic mechanism. Decreased microtubule-severing activity leads to impaired axonal transport and distal axonal degeneration, ultimately resulting in progressive spastic paraplegia [3,6]. There is currently no disease-modifying therapy for SPG4; clinical management is mainly symptomatic treatment of spasticity.
The p.Arg499His (R499H) variant is a missense mutation in the SPAST gene caused by a nucleotide substitution at c.1496G>A (NM_014946.4), resulting in the replacement of arginine (Arg) with histidine (His) at amino acid position 499 of the Spastin protein. This variant is located within the AAA domain of Spastin and may affect its normal function. It has been reported in multiple clinical studies to be associated with hereditary spastic paraplegia type 4 (SPG4). Affected individuals may exhibit infantile-onset symptoms, including lower limb spasticity and delayed motor development. Some cases may also present with dystonia, dysarthria, and cognitive impairment [7-8].
huSPAST-HA-R499H mice were generated using gene-editing technology by replacing the sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the human TAA stop codon, and the p.R499H (CGT to CAT) mutation was introduced into exon 13 of the human SPAST gene. This model can be used to investigate the pathogenesis of hereditary spastic paraplegia type 4 (SPG4) associated with the SPAST R499H mutation, as well as to support the development and efficacy evaluation of targeted therapeutics.
Reference
Salinas S, et al. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008;7(12):1127-1138.
Ruano L, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174-183.
Fonknechten N, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9(4):637-644.
Zhao M, et al. Genetic and Clinical Profile of Chinese Patients with Autosomal Dominant Spastic Paraplegia. Mol Diagn Ther. 2019;23(6):781-789.
Roll-Mecak A, et al. Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin. Nature. 2008;451(7176):363-367.
Patrono C, et al. Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. J Neurol. 2002;249(2):200-205.
Nan H, et al. A p.Arg499His mutation in SPAST is associated with infantile-onset complicated spastic paraplegia: a case report and review of the literature. BMC Neurol. 2021 Nov 9;21(1):439.
Mo A, et al. Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST. Mov Disord. 2022 Dec;37(12):2440-2446.
변형 전략
The sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene was replaced with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the TAA stop codon of the human SPAST gene, and the p.R499H (CGT to CAT) mutation was introduced into human SPAST exon 13.

Figure 1. Gene editing strategy of huSPAST-HA-R499H mice.
응용 분야
Research on the pathogenesis of hereditary spastic paraplegia type 4 (SPG4);
Screening, development, and preclinical in vivo evaluation of SPAST-targeted therapies.
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
